miR-217 targeting DKK1 promotes cancer stem cell properties via activation of the Wnt signaling pathway in hepatocellular carcinoma

CHUNLIN JIANG1,2*, MIAO YU3*, XIAOYAN XIE1,2, GUANGLIANG HUANG1,2, YAO PENG5, DONG REN6, MANXIA LIN1,2, BAOXIAN LIU1,2, MING LIU1,2, WEI WANG1 and MING KUANG2,4

1Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, 2Division of Interventional Ultrasound, 3Center for Private Medical Service and Healthcare, Departments of 4Liver Surgery, 5Gastroenterology and 6Orthopaedic Surgery/Orthopaedic Research Institute, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China

Received November 8, 2016; Accepted May 24, 2017

DOI: 10.3892/or.2017.5924

Abstract. Hepatocellular carcinoma (HCC) is one of the most common malignancies and exhibits heterogeneity in terms of clinical outcomes and biological activities. Emerging evidence has demonstrated that cancer stem cells (CSCs) play important roles in the tumorigenesis and progression of HCC. However, the molecular mechanisms underlying the stemness maintenance of CSCs remain largely unknown. In the present study, through real-time PCR, western blotting, luciferase assays, RNA immunoprecipitation, and in vitro and in vivo assays, we demonstrated that miR-217 expression was markedly increased in HCC tissues and cells. Overexpression of miR-217 promoted, while silencing miR-217 suppressed, the fraction of the side population and the expression of cancer stem cell factors in vitro and tumorigenicity in vivo in HCC cells. Our findings further demonstrated that miR-217 promoted the CSC-like phenotype via dickkopf-1 (DKK1) targeting, resulting in constitutive activation of Wnt signaling. Moreover, the stimulatory effects of miR-217 on stem cell properties and Wnt signaling were antagonized by the upregulation of DKK1 in miR-217-overexpressing cells. Conversely, the inhibitory effects of silencing miR-217 on stem cell properties and Wnt signaling were reversed by the downregulation of DKK1 in miR-217-downregulated cells. Therefore, our results indicate that miR-217 plays a vital role in the CSC-like phenotypes of HCC cells and may be used as a potential therapeutic target against HCC.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the third-leading cause of cancer-related deaths worldwide (1). Despite great progress in systemic management and treatment in recent years, the 5-year survival rate is still poor, ~15%, where locoregional and distant recurrences remain primary issues due to widespread intrahepatic and extrahepatic metastases (2). Therefore, it is of great urgency to explore the molecular mechanisms responsible for HCC development and progression, which may help to identify new antitumor strategies against HCC.

Cancer stem cells (CSCs) are a minority cell population within tumors and are characterized by unlimited proliferation as well as the abilities of self-renewal and differentiation into heterogeneous lineages of cancer cells that constitute the major tumor population (3,4). Emerging evidence has demonstrated that CSCs play a crucial role in the progression of different types of cancer (5,6). The existence of CSCs was first reported in acute myeloid leukemia (7), and broad identification was further demonstrated in several solid tumors, including colon (8), pancreas (9) and breast cancer (10), indicating the ubiquitous existence of CSCs in tumors. Furthermore, increasing evidence has suggested that CSCs are the critical initiators of HCC. Lee et al reported that CD24+ cells drive tumor initiation through STAT3-mediated NANOG regulation in HCC (11). Moreover, a monoclonal antibody against CSCs, 1B50-1, decreased self-renewal and tumor formation capacities and induced apoptosis of CSCs in HCC (12). This evidence indicated that therapeutic methods targeting CSCs may be efficient avenues in the treatment of HCC.

MicroRNAs (miRNAs) are non-coding 17- to 25-nucleotide-long RNAs that function by binding to the 3′-untranslated (3′UTR) region of downstream mRNAs and regulate gene expression post-transcriptionally (13). Physiologically, miRNAs play important roles in various cellular functions, including cell apoptosis, proliferation and differentiation (14). Furthermore, miRNAs also play a pivotal role in the stemness maintenance of CSCs, including HCC (15,16). For example,
Ma et al reported that microRNA expression profiling of CD133+ and CD133− cells from human HCC clinical specimens and cell lines identified an overexpression of miR-130b in CD133+ CSCs. Ectopic expression of miR-130b in CD133− cells enhanced self-renewal ability and tumorigenicity in vivo. Conversely, antagonizing miR-130b in CD133+ CSCs exhibited an opposing effect (17). In addition, another study indicated that miR-181, which was found to be overexpressed in EpCAM+ HCC cells isolated from AFP+ tumors, promoted tumor-initiating ability. Notably, inhibition of miR-181 led to a decrease in tumor-initiating ability (18). Therefore, these studies demonstrated that miRNAs play important roles in regulating CSC-like phenotypes in HCC.

In the present study, we found that miR-217 was upregulated in HCC tissue samples and cells. Moreover, upregulation of miR-217 enhanced the stem cell properties of HCC cells via DKK1 targeting. Notably, the pro-CSC-like phenotype role of miR-217 was attenuated by overexpression of dickkopf-1 (DKK1) in HCC cells. Thus, our results revealed a novel mechanism by which miR-217 promoted a CSC-like phenotype in HCC, and anti-HCC therapy targeting miR-217 may be a potential therapeutic strategy for the treatment of HCC.

Materials and methods

Cell lines and cell culture. The human HCC cell lines 97H, HepG2, QGY-7703, Hep3B, PLC, HuH7 and SMMC7721 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA), and all human HCC cell lines were cultured as described in the ATCC protocol. Human liver immortal cell line L02 was purchased from Biomics Biotechnologies (Nantong, China). The cell lines were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and 100 U/ml penicillin plus 100 µg/ml streptomycin. The cells were grown in a humidified atmosphere of 5% CO2 at 37°C.

Plasmids, transfection and generation of stable cell lines. The miR-217-expression plasmid was generated by cloning the genomic pre-miR-217 gene, with a 300-bp sequence on each flanking side, into retroviral-transfer plasmid pMSCV-puro (Clontech Laboratories, Inc., Mountain View, CA, USA) to generate plasmid pMSCV-miR-217. pMSCV-miR-217 was cotransfected with the pIK packaging plasmid in 293FT cells cotransfected with the pIK packaging plasmid in 293FT cells using the standard calcium phosphate transfection method, as previously described (21). The following cell lines were used to establish stable transduction: CD133− and CD133+ cells from human HCC clinical specimens and cell lines. The cells were cultured as described in the ATCC protocol. Human liver immortal cell line L02 was purchased from Biomics Biotechnologies (Nantong, China). The cell lines were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and 100 U/ml penicillin plus 100 µg/ml streptomycin. The cells were grown in a humidified atmosphere of 5% CO2 at 37°C.

Western blotting. Western blotting was performed according to a standard method, as previously described (22). The following primary antibodies were used: anti-DKK1, anti-β-catenin,
and α-tubulin (BD Pharmingen; BD Biosciences, San Diego, CA, USA) and p84 (Abcam, Cambridge, MA, USA). Nuclear extracts were prepared using the Nuclear Extraction kit (Active Motif, Carlsbad, CA, USA), according to the manufacturer's instructions.

**Luciferase reporter assay.** Cells were seeded in triplicate in 24-well plates, and allowed to settle for 24 h. Indicated plasmids plus 1 ng pRL-TK Renilla plasmid were transfected into the cells using Lipofectamine 3000 reagent (Life Technologies). Forty-eight hours after transfection, a Dual-Luciferase Reporter Assay (Promega, Madison, WI, USA) was performed according to the manufacturer's instructions, as previously described (22).

**Tumor xenografts.** All experimental procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University. Six-week-old BALB/c-nu mice were randomly divided into 4 groups (n=6/group). The cells (1x10⁵) were subcutaneously inoculated along with Matrigel (final concentration of 25%) into the inguinal folds of the nude mice. The tumor volume was determined using an external caliper and calculated using the equation (L x W²)/2. The mice were sacrificed 35 days after inoculation and the tumors were excised and subjected to pathological examination.

**Side population analysis.** The cell suspensions were labeled with Hoechst 33342 (molecular probes, #H-3570) dye for side population (SP) analysis as per standard protocol (23). Briefly, cells were resuspended at 1X pre-warmed Opti-MEM (containing 2% FBS) (both from Gibco, Grand Island, NY, USA) at a density of 10⁶ cells/ml. Hoechst 33342 dye was added at a final concentration of 5 µg/ml in the presence or absence of verapamil (50 µmol/l; Sigma-Aldrich, St. Louis, MO, USA) and the cells were incubated at 37°C for 90 min with intermittent shaking. At the end of the incubation period, the cells were washed with Opti-MEM containing 2% FBS and centrifuged at 4°C, and subsequently resuspended in ice-cold Opti-MEM containing 2% FBS and 10 mmol/l HEPES. Then, propidium iodide (Sigma-Aldrich) at a final concentration of 2 µg/ml was added to the cells to gate viable cells. The cells were filtered through a 40-µm cell strainer to obtain a single cell suspension before sorting. Analysis and sorting was carried out on a FACSaria I (Becton-Dickinson, Franklin Lakes, NJ, USA). The Hoechst 33342 dye was excited at 355 nm and its dual-wavelength emission at the blue and red regions was plotted to get the SP scatter.

**miRNP immunoprecipitation.** Cells were co-transfected with HA-Ago1 along with 100 nM miR-217, followed by HA-Ago1 immunoprecipitation using an HA-antibody. Real-time PCR analysis of the IP material was used to assess the association of the mRNA of DKK1 with the RISC complex.

**Statistical analysis.** All statistical analyses were carried out using the SPSS 16.0 statistical software package. Comparisons between groups for statistical significance were performed using Chi-square and Fisher's exact tests. In all cases, P<0.05 was considered significant. All the experiments were repeated 3 times.

**Table II.** Relationship between miR-217 and the clinicopathological characteristics in 64 hepatocellular carcinoma patients.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No. of cases</th>
<th>High</th>
<th>Low</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>37</td>
<td>20</td>
<td>17</td>
<td>0.448</td>
</tr>
<tr>
<td>Female</td>
<td>27</td>
<td>12</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>33</td>
<td>14</td>
<td>19</td>
<td>0.211</td>
</tr>
<tr>
<td>≥60</td>
<td>31</td>
<td>18</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>AFP (ng/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400</td>
<td>30</td>
<td>9</td>
<td>21</td>
<td>0.003*</td>
</tr>
<tr>
<td>≥400</td>
<td>34</td>
<td>23</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>&lt;5</td>
<td>38</td>
<td>11</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>26</td>
<td>21</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>33</td>
<td>20</td>
<td>13</td>
<td>0.080</td>
</tr>
<tr>
<td>Low</td>
<td>31</td>
<td>12</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>30</td>
<td>11</td>
<td>19</td>
<td>0.045*</td>
</tr>
<tr>
<td>III-IV</td>
<td>34</td>
<td>21</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Venous invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>26</td>
<td>9</td>
<td>17</td>
<td>0.042*</td>
</tr>
<tr>
<td>Positive</td>
<td>38</td>
<td>23</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>45</td>
<td>8</td>
<td>19</td>
<td>0.006*</td>
</tr>
<tr>
<td>Positive</td>
<td>35</td>
<td>24</td>
<td>13</td>
<td></td>
</tr>
</tbody>
</table>

*P<0.05. AFP, α-fetoprotein.

**Results**

**miR-217 is upregulated in HCC tissues and cells.** To identify the potential miRNAs in HCC, we analyzed the HCC datasets from The Cancer Genome Atlas (TCGA). The result revealed that miR-217 was upregulated in HCC tissues compared with normal hepatic tissues (Fig. 1A). We further analyzed the miR-217 expression in 49 paired HCC tissues from TCGA and found that the expression levels of miR-217 were upregulated in the primary HCC tissues compared with the matched adjacent normal tissues (Fig. 1B). Furthermore, we assessed the miR-217 expression in our own HCC tissue samples (Table II). As shown in Fig. 1C and D, miR-217 expression was markedy increased in HCC tissues compared with that in normal hepatic tissues, and the matched adjacent normal tissues, respectively. We further examined the expression level of miR-217 in HCC cells and found that compared to human liver immortal cell line L02, the expression of miR-217 was differentially upregulated in HCC cells. Thus, our findings demonstrated that miR-217 is increased in HCC tissues and cells.
Figure 1. miR-217 is upregulated in HCC tissues and cells (A) The expression level of miR-217 in normal hepatic tissues and HCC tissues in the miRNA sequencing dataset of TCGA HCC (normal, n=50; hepatocellular carcinoma, n=372). P<0.001. (B) The expression level of miR-217 in 49 paired primary HCC tissues compared with matched adjacent normal tissues. The transcript levels were normalized to U6 expression. P<0.001. (C) Real-time PCR analysis of miR-217 expression in 64 HCC tissues compared to 6 normal hepatic tissues. The transcript levels were normalized to U6 expression. P<0.05. (D) The expression level of miR-217 in 6 paired primary HCC tissues compared with matched adjacent normal tissues. The transcript levels were normalized to U6 expression. *P<0.05. (E) The expression level of miR-217 in one normal hepatic cell line and 7 HCC cell lines. *P<0.05. TCGA, The Cancer Genome Atlas; HCC, hepatocellular carcinoma.

Figure 2. miR-217 promotes the CSC population of HCC in vitro and in vivo. (A) Real-time PCR analysis of miR-217 expression after transfection with miR-217 mimics or inhibitor in HCC cells. (B) Hoechst 33342 dye exclusion assay showing that upregulation of miR-217 increased the side population, whereas silencing of miR-217 decreased the side population. Error bars represent the mean±SD of three independent experiments. *P<0.05. (C) Real-time PCR analysis of NANOG, BMI-1, OCT4 and SOX2 expression. GAPDH was used as the loading control. Error bars represent the mean ± SD of 3 independent experiments. *P<0.05. (D) Representative images of the tumors are shown in the xenograft model of nude mice. Tumors formed by the miR-217-overexpressing Huh7 cells were larger than the control tumors. Conversely, tumors formed by the anti-miR-217 cells were smaller than tumors formed by the NC vector cells. (E) Growth curves for tumor formation after implantation (n=6/group). Mean tumor volumes are plotted. *P<0.05. (F) A dot plot displaying the mean tumor weights of each group (n=6/group). *P<0.05. CSC, cancer stem cell; HCC, hepatocellular carcinoma.
miR-217 promotes stem cell properties and tumorigenesis in HCC cells. Accumulating studies have suggested that cancer growth is driven by CSCs (24,25). To further investigate the role of miR-217 in the CSC-like phenotype of HCC cells, we first constructed miR-217-stably expressing cells by ectopically overexpressing miR-217 and endogenously silencing miR-217 via retrovirus infection in the HepG2 and Huh7 cell lines (Fig. 2A). The effect of miR-217 on the SP was examined and the result revealed that overexpression of miR-217 increased, while silencing miR-217 decreased the fraction of SP cells in the HepG2 and Huh7 cells (Fig. 2B). We further assessed the effect of miR-217 on stem cell markers, including Nanog homeobox (NANOG), proto-oncogene polycomb ring finger (BMI1), POU class 5 homeobox 1A (OCT4A) and SOX2, and found that upregulation of miR-217 enhanced the expression of these markers. However, knockdown of miR-217 decreased the expression of these markers (Fig. 2C). Collectively, these results indicated that miR-217 promotes CSC-like phenotypes in HCC in vitro.

We next assessed the effect of miR-217 on the tumorigenesis of HCC in vivo. Huh7 cells (1x10⁵) of the miR-217-overexpressing, control and anti-miR-217 cells were inoculated into nude mice, respectively. As shown in Fig. 2D-F, tumors in the miR-217-overexpressing group grew more rapidly than those in the control group. Conversely, tumors in the anti-miR-217 group were smaller than the tumors in the negative control group. These results revealed that miR-217 promotes the tumorigenesis of HCC cells in vivo.

miR-217 targets a negative regulator of the Wnt signaling pathway. By the publicly available algorithms TargetScan and miRNA.ORG, we found that the negative regulator of Wnt signaling, DKK1, may be a potential target of miR-217 (Fig. 3A). PCR and western blotting revealed that miR-217 overexpression decreased, while silencing of miR-217 increased the expression of DKK1 (Fig. 3B and C). Luciferase assay revealed that miR-217 overexpression decreased, while
silencing of miR-217 enhanced the reporter activity driven by the 3’UTRs of DKK1 in dose-dependent manners, but not by the mutant 3’UTRs of DKK1 within the miR-217-binding seed regions in HCC cells (Fig. 3D and E). Furthermore, microribonucleoprotein (miRNP) immunoprecipitation (IP) assay demonstrated a selective association of miR-217 with DKK1 transcript (Fig. 3F), further elucidating the direct suppressive effect of miR-217 on DKK1. Consequently, our results indicate that DKK1 is an authentic target of miR-217 in HCC cells.

miR-217 activates Wnt signaling pathways in HCC cells. We next investigated the effect of miR-217 on Wnt signaling. As shown in Fig. 4A, western blotting revealed that overexpression of miR-217 increased nuclear accumulation of β-catenin, while silencing of miR-217 impaired the β-catenin translocation into the nucleus. Furthermore, we found that miR-217 overexpression increased, while silencing of miR-217 decreased, β-catenin/TCF transcriptional activity (Fig. 4B). We further examined the expression levels of multiple downstream genes of Wnt signaling, including c-myc, LEF1 and TCF1 and found

"Figure 4. miR-217 activates the Wnt signaling pathway. (A) Western blotting of nuclear β-catenin expression. The nuclear protein p84 was used as the nuclear protein marker. (B) TOP/FOP luciferase assay of TCF/LEF transcriptional activity in the indicated cells. Error bars represent the means±SD of 3 independent experiments. *P<0.05. (C-E) Real-time PCR analysis of c-myc, LEF1 and TCF1 expression in the indicated cells. *P<0.05."
that overexpression of miR-217 enhanced the expression of c-myc, LEF1 and TCF1, while silencing of miR-217 yielded the opposite effect (Fig. 4C-E). Thus, these results demonstrated that miR-217 activates the Wnt signaling pathway.

DKK1 mediates miR-217-induced CSC phenotypes in HCC cells. To explore whether DKK1 contributed to miR-217-induced CSCs, we transfected the DKK1 plasmid in miR-217-overexpressing cells and RNA interference of DKK1 in miR-217-silenced cells, respectively. β-catenin/TCF transcriptional activity assay revealed that the stimulatory effect of miR-217 was anagonted by the upregulation of DKK1 and the inhibitory effect of anti-miR-217 was reversed by DKK1 RNAi (Fig. 5A). Furthermore, the upregulation of DKK1 in miR-217-overexpressing cells significantly decreased the SP. In contrast, knockdown of DKK1 in miR-217-silenced cells increased the fraction of SP in HCC cells (Fig. 5B). Real-time PCR revealed that DKK1 contributed to the expression of stem cell markers regulated by miR-217 (Fig. 5C). Collectively, these results suggest that DKK1 mediates the regulatory role of miR-217 in CSC-like phenotypes in HCC cells.

Clinical correlation of miR-217 with DKK1 expression in HCC tissues. To further investigate whether the expression of miR-217 was associated with DKK1 expression in HCC clinical tissue samples, the expression levels of miR-217 were examined in 10 HCC fresh tissues by real-time PCR. As shown in Fig. 6A and B, there was a significant negative correlation between miR-217 and DKK1 \( (r=-0.693; \ P<0.05) \) in HCC. Furthermore, we found that the expression of miR-217 was increased in HCC tissues with low DKK1 expression when compared to those with high DKK1 expression (Fig. 6C). Collectively, these results demonstrated that miR-217 is negatively correlated with DKK1 expression in HCC tissues.

Discussion

In the canonical Wnt pathway, Wnt ligands bind to frizzled receptors and lipoprotein receptor-related protein-5 or -6 (LRP5/6) co-receptors, giving rise to the accumulation and subsequent translocation of β-catenin into the nucleus. Then, nuclear β-catenin interacts with the T-cell factor (TCF) family of transcription factors to initiate the transcription of downstream target genes (26,27). Notably, several cancer stem cell factors, including CD44, NANOG, SOX2 and OCT4, are well-known targets of the Wnt pathway, indicating that the Wnt signaling pathway plays crucial roles in the regulation of CSCs (28,29).

Furthermore, the constitutive activation of Wnt/β-catenin signaling has been implicated in a variety of human cancers, including hepatocellular carcinoma (HCC) (30,31). Indeed, 40~70% of HCC has been reported to harbor nuclear accumulation of the downstream effector β-catenin of Wnt signaling (32). Wong et al reported that constitutive activation of Wnt signaling induced the increased translocation of β-catenin into the nucleus, which contributed to the development of HCC (33). These studies demonstrated that dysregulation of Wnt signaling is a critical driver of HCC pathogenesis. In the present study, we revealed that miR-217 was increased in HCC tissues and cells. Overexpression of miR-217 increased, while silencing of miR-217 decreased the nuclear translocation of β-catenin, β-catenin/TCF transcriptional activity as well as the expression levels of downstream genes of the Wnt signaling pathway, which further contributed to the CSC-like phenotype in HCC cells. Our results further revealed that miR-217 activates the Wnt signaling pathway via DKK1 targeting, an important negative regulator of Wnt signaling. Therefore, our findings uncovered a novel mechanism of miR-217 in the regulation of the Wnt signaling pathway.

Dickkopf-1 (DKK1) which acts as an important negative regulator of Wnt/β-catenin signaling functions via binding with high affinity to LRP5/6 in competition with Wnt (34). DKK1 has been reported to be downregulated in various cancers, resulting in the constitutive activation of the Wnt/β-catenin signaling pathway (35,36). Furthermore, several studies have reported that the upregulation of DKK1 inhibited sphere formation capacity and decreased the CD24+/CD44+ cell population in breast cancer cells (37). This evidence indicated that DKK1 played an important role in the stemness maintenance of CSCs. In the present study, RT-PCR and western blotting revealed that overexpressing miR-217 decreased, while silencing miR-217 increased the mRNA and protein levels of DKK1. Luciferase and miRNP IP assay demonstrated the...
association of miR-217 with DKK1 in HCC cells, indicating that DKK1 is a direct target of miR-217 in HCC cells. Notably, the stimulatory effects of miR-217 on β-catenin/TCF transcriptional activity and CSC-like phenotype was antagonized by overexpression of DKK1 in miR-217-overexpressing cells. Conversely, silencing of DKK1 yielded the opposite effect in miR-217-downregulating cells. Collectively, these findings demonstrated that miR-217 promotes a CSC-like phenotype and activates Wnt signaling via DKK1 targeting in HCC cells.

miR-217 has been identified to be downregulated in multiple human cancers, and has contributed to cancer cell proliferation, drug resistance and metastasis via varying mechanisms (38-41). Furthermore, the expression of miR-217 has also been found to be upregulated in gastric and breast cancer (42,43). These findings indicated that miR-217 functions as both an oncomir and tumor-suppressive miRNA, depending on the tumor type. Notably, several studies have reported that miR-217 was increased in HCC (44,45), however the specific mechanisms responsible for the progression of HCC remain poorly elucidated. Consistent with these findings, we revealed that miR-217 was upregulated in HCC tissues and cells. Overexpression of miR-217 promoted, while silencing miR-217 suppressed, the CSC-like phenotypes in vitro and tumorigenicity in vivo in HCC cells. Our findings further demonstrated that miR-217 promotes the CSC-like phenotype via DKK1 targeting, resulting in constitutive activation of Wnt signaling. Moreover, the stimulatory or inhibitory effects of the upregulation or downregulation of miR-217 on stem cell properties and Wnt signaling were antagonized by the upregulation or downregulation of DKK1 in HCC cells. Notably, another study reported that miR-217 expression was much lower in highly invasive MHCC-97H HCC cells and metastatic HCC tissues. Ectopic expression of miR-217 inhibited the invasion of MHCC-97H cells. Inversely, inhibition of miR-217 enhanced the invasive ability of Huh7 and MHCC-97L cells (46). This evidence demonstrated that miR-217 plays different or even contradicting roles in the different developmental processes of HCC.

In summary, the present study demonstrated that oncogenic miR-217 promotes CSC-like properties and tumorigenicity by negatively regulating DKK1, leading to activation of the Wnt/β-catenin signaling pathway in HCC. Improved understanding of the specific role of miR-217 in the activation of the Wnt signaling pathway and in the pathogenesis of HCC may help to develop novel therapeutic methods in the treatment of HCC.

Acknowledgements

The present study was supported by the State Key Program of the National Natural Science Foundation of Guangdong, China (Program, no. 2015A030311039), the National Natural Science Foundation of China (81272312) and the Science and Technology Planning Project of Guangdong Province, China (no. 2014A020212390).

References


